ArticleNature communications2026
Novel CuCLIP-seq for in situ covalently captured protein-binding RNAs.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
RNA binding proteins (RBPs) are multi-faceted proteins that interact with transcripts in various RNA driven processes and functions. However, in situ covalent capture techniques for screening authentic RNA substrates of RBPs remain challenging in terms of reproducibility, specificity, and sensitivity. Here, we developed CuCLIP-seq (CuAAC-Crosslinking and Immunoprecipitation Sequencing), an alternative in situ covalent capture sequencing method which utilizes CuAAC reaction to crosslink RBP-RNA between azido groups of RBPs and ethynyl groups of RNA molecules, followed by streptavidin-mediated enrichment of RNA substrates and high-throughput sequencing. We demonstrate the reliability of CuCLIP-seq by identifying substrate RNAs of several RBPs, including PTBP1, ADAR2, SRSF2, HNRNPA1, and PINX1, especially for capturing low-abundance targets. Additionally, this approach is authenticated by specifically resolving the alternative splicing transcripts targeted by PTBP1 and RNA targets by PINX1. Thus, this technique offers a sensitive and specific approach for detecting RBP substrates with high reproducibility, potential scalability, and wide applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.